Biopharma companies that have struggled to make a splash in the U.S. or European markets with their new treatments are increasingly turning to China for a reprieve.
Sanofi Pasteur and the University of Georgia this week talked up details of a next-gen flu vaccine strategy that the pair hopes can build on the strength of current vaccines but broaden protection to avoid the problems associated with strain drift.
Texas is adding more eggs to its incubator as cancer biopharma Tesaro has inked a deal with UT's MD Anderson Cancer Center for new immuno-oncology targets.
Snapdragon Chemistry is expanding its team, working space, and corporate partnership and has elected a new CEO in a major update from the privately held CRO.
Japan has approved a new biosimilar of Sanofi's blockbuster Lantus (insulin glargine) as its creator Biocon chalks up a much-needed win after a tough 2015.
Dr. Reddy's Laboratories has signed a $490 million drug licensing deal with California's XenoPort as the struggling biotech looks to shed its R&D; ahead of a rumored sale of the company.
The metalloproteins specialist Forge Therapeutics and Active Motif, which develops tools to help "turn off" certain genes, have penned a new deal in epigenetic research.
New life science firms hoping to get off the ground in South Korea will be able to receive extra funding help as the government announces plans to boost more startups in the region.
The Paul G. Allen Frontiers Group has officially launched today as the life sciences funding arm of the Allen Institute. The Group, headquartered in Seattle, WA, has been set up by the multi-millionaire Microsoft co-founder.
The world's biggest CRO Quintiles and a number of international investors have come together to create a new fund aimed at lightening the cost burden of pharma drug development.